Ray K K, Cannon C P, Braunwald E
Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Int J Clin Pract. 2007 Jul;61(7):1145-59. doi: 10.1111/j.1742-1241.2007.01425.x.
The global burden of coronary artery disease has pushed lipid-lowering therapy to the forefront of medical management of this condition. Recent clinical trials have compared the efficacy of more intensive lipid lowering with statins against the normal standard of care. Other agents such as fibrates, glitazones, which also favourably modify lipid levels have also been assessed recently. This narrative review summarises the key recent clinical trials of lipid lowering since 2004 and their implications for future patient care.
冠状动脉疾病的全球负担已将降脂治疗推至这种疾病医疗管理的前沿。近期的临床试验比较了强化他汀类药物降脂与常规标准治疗的疗效。其他一些同样能有效改善血脂水平的药物，如贝特类药物、格列酮类药物，近期也已得到评估。这篇叙述性综述总结了2004年以来近期降脂治疗的关键临床试验及其对未来患者护理的意义。
